AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells.
about
AMP-activated protein kinase, stress responses and cardiovascular diseasesEnergy disruptors: rising stars in anticancer therapy?Regulation of Bim in Health and DiseaseRole of AMP-activated protein kinase on steroid hormone biosynthesis in adrenal NCI-H295R cellsBcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II studyUse of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activationDesynchronization of Circadian Clocks in Cancer: A Metabolic and Epigenetic Connection.Evolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer.MondoA senses adenine nucleotides: transcriptional induction of thioredoxin-interacting proteinMetabolomics Analysis Reveals that AICAR Affects Glycerolipid, Ceramide and Nucleotide Synthesis Pathways in INS-1 Cells.Targeting AMPK for cancer prevention and treatment.N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for cancer therapy.Modulator of Apoptosis 1: A Highly Regulated RASSF1A-Interacting BH3-Like ProteinTargeting antiapoptotic A1/Bfl-1 by in vivo RNAi reveals multiple roles in leukocyte development in miceMicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid MalignanciesAssociation of AMP-activated protein kinase with risk and progression of non-Hodgkin lymphoma.The pentacyclic triterpenoid, plectranthoic acid, a novel activator of AMPK induces apoptotic death in prostate cancer cells.Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK.A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis.Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphomaMetformin induces PGC-1α expression and selectively affects hepatic PGC-1α functions.LKB1 loss of function studied in vivo.PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis.Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia.Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies.The multifaceted activities of AMPK in tumor progression--why the "one size fits all" definition does not fit at all?Apoptosis inducers in chronic lymphocytic leukemia.5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranosyl 5'-Monophosphate (AICAR), a Highly Conserved Purine Intermediate with Multiple Effects.Targeting PI3K/AKT/mTOR network for treatment of leukemia.Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?Small molecules as therapy for uveitis: a selected perspective of new and developing agents.Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.AMPK Regulation of Cell Growth, Apoptosis, Autophagy, and Bioenergetics.A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer.Metabolomics identifies pyrimidine starvation as the mechanism of 5-aminoimidazole-4-carboxamide-1-β-riboside-induced apoptosis in multiple myeloma cells.AMPK-dependent and independent effects of AICAR and compound C on T-cell responses.Aerobic Exercise Training Selectively Changes Oxysterol Levels and Metabolism Reducing Cholesterol Accumulation in the Aorta of Dyslipidemic Mice.Synthesis of new acadesine (AICA-riboside) analogues having acyclic D-ribityl or 4-hydroxybutyl chains in place of the ribose.Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
P2860
Q24610297-C45B66F3-E249-4031-AEAD-014F87572E0BQ26771300-6021F4A3-90AF-4A2E-9299-B06B5DF6374CQ26781203-8FB70967-0903-4D2C-8618-8B22F173FDAEQ28479180-7EE19D42-8B5A-4957-B965-924956DF6263Q30395557-AD5C0F7D-E240-4DCC-9D30-551BAB9CE756Q33404763-725382B1-569A-4B12-876B-EF326227B560Q33645356-2818AFEA-06AF-43BE-9383-DF593293B82EQ33809578-AF5DE5BE-A3C5-4050-A8AF-9642009B432AQ34506762-675E8DEE-2295-45B9-8769-2521796EC952Q35619861-B1C27A5E-D53C-48F5-9A0F-009969B032E5Q35673036-9F7BC475-7A37-4D3E-96CA-100EDA66430BQ35781311-7ED37601-F217-4FD1-A8A2-7B3A8BDE5006Q36055168-22A4CCF7-D627-4822-ABA2-50B05480C87DQ36056087-1930819A-FBBF-48F5-A8A3-B452CC0C8309Q36163201-12265260-1C30-4AE1-8E12-1C3A80E7F4B4Q36602853-4A200466-FAE2-4978-B95B-837EBB762DACQ36780387-71F36247-2360-45B8-8BA4-2955AE440692Q36782275-B312E7C6-AF18-4451-BA22-C0286F6B93F7Q37543714-5B786B1A-EB6B-4FF5-A0CA-DA02211FAB4CQ37710823-473D6E45-BF24-4C4C-A3A5-C45E21EBCB12Q37718466-18A60DC7-B253-408A-A7B8-54B19EB6784BQ37719411-C192989E-3F19-4EC3-8E49-F4002872E4B7Q37829489-3440CCB8-66AA-4C05-AEE7-5051EC7F08A8Q37974734-8EB73FD5-2EA0-4FE3-B4EE-511D8054AC50Q37997623-54199478-030D-4536-83B3-247201E674F4Q38017727-23790EF1-4A01-4965-A211-1E194E8A3771Q38165133-29F1E373-5E91-4EB8-B67E-8297BB1F4118Q38187815-CA3DCB34-ED24-460D-8A4E-EC956FD23CCCQ38222605-6CC7086A-9FDB-405D-8DFA-2A41F8A3BDF1Q38364871-F64873E5-F98F-41C6-AFB2-99593E7B5D01Q38606849-13A93D63-5A58-4828-9E57-F3C34C447F8AQ38650868-9CDFF686-EFD0-4A78-86A1-4BC3C7EAD426Q38947158-D830A049-DE7A-4E8B-B481-0D2056D6F14DQ38998395-77BB8620-9445-48DC-866D-12006834AA92Q39124486-B455E648-E4A7-4A60-94C1-BB0AF2CAC936Q39435452-449E3D06-9543-4053-8387-A68053C92ECAQ39768288-EAB2983B-4A20-44C0-8138-267DBC207682Q41454286-53F185A9-9E44-4AB1-99D9-D9E23529A68AQ42278323-E0DB0E03-B077-4534-810B-31BFF94E1005Q43067104-AEDFDB26-A073-4444-B1FF-1112CFF7C826
P2860
AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
AICAR induces apoptosis indepe ...... ic lymphocytic leukemia cells.
@en
AICAR induces apoptosis indepe ...... ic lymphocytic leukemia cells.
@nl
type
label
AICAR induces apoptosis indepe ...... ic lymphocytic leukemia cells.
@en
AICAR induces apoptosis indepe ...... ic lymphocytic leukemia cells.
@nl
prefLabel
AICAR induces apoptosis indepe ...... ic lymphocytic leukemia cells.
@en
AICAR induces apoptosis indepe ...... ic lymphocytic leukemia cells.
@nl
P2093
P50
P1433
P1476
AICAR induces apoptosis indepe ...... nic lymphocytic leukemia cells
@en
P2093
Adalberto Benito
Ana M Cosialls
Andreas Villunger
Antonio F Santidrián
Clara Campàs
Diana M González-Gironès
Esther Alonso
Gabriel Pons
Llorenç Coll-Mulet
Mercè de Frias
P304
P356
10.1182/BLOOD-2010-05-283960
P407
P577
2010-07-27T00:00:00Z